Quick Answer
CASI Pharmaceuticals, Inc. reported Gross Profit of $11.15 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $11.15M | -44.4% |
| 2023 | $20.05M | -26.5% |
| 2022 | $27.28M | +54.9% |
| 2021 | $17.61M | +212.6% |
| 2020 | $5.63M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -44.4% in Gross Profit compared to the prior fiscal year.
- Over the 2020–2024 period, CASI Pharmaceuticals, Inc.’s gross profit has grown by 97.9% (from $5.63 million to $11.15 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: